No Data
No Data
Nomura Adjusts WuXi Biologics (Cayman)'s Price Target to HK$23.25 From HK$53.65, Keeps at Buy
Wuxi Biologics Stock Looks Undervalued -- Market Talk
Wuxi Biologics Target Price Cut to HK$23.25 From HK$53.65 by Nomura >2269.HK
Contract research organizations are generally increasing. Pharmaron (03759) rose 6.66%, and Orient Securities is expected to see marginal improvement in the sector.
Jingu Financial News| The concept of contract research organizations is rising across the board. As of the time of publication, Pharmaron (03759) rose 6.66%, Viva Biotech (01873) rose 5.05%, Tigermed (03347) rose 2.84%, and Wuxi Bio (02269) rose 2.77%. On the news side, Orient Securities stated that according to the latest data on the key indicators of the CRO industry's prosperity index, the global fund has basically stabilized, while the domestic investment and financing side is still tight; however, the enthusiasm for research and development has not diminished, and the IND and new clinical trials are still at a high level. The bank believes that the CXO sector, after experiencing double killings in performance and valuation, is expected to welcome a
Unusual event report | CRO concept stocks rose collectively, with the top companies signing new orders with double-digit growth in amount, and the sector is expected to see marginal improvement.
CRO concept stocks collectively rose. As of press time, Pharmaron (03759) rose 7.23% to HKD 9.34, Viva Biotech (01873) rose 3.03% to HKD 0.51, and Tigermed (03347) rose 2.84% to HKD 30.75.
Trending Industry Today: FRONTAGE Leads Gains In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
No Data